Vincamine Derivatives for Blood-Brain Barrier Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering nucleic acid drugs across the blood-brain barrier face challenges due to the barrier's impermeability, leading to low bioavailability and potential toxicity from conventional cationic lipid materials, necessitating frequent administration and posing risks like neurotoxicity and immunogenicity.
Innovation Solution
Development of vincamine derivatives with modified tail chains and ionizable tertiary amine groups to enhance lipophilicity and charge-mediated delivery, facilitating penetration across the blood-brain barrier and improving intracellular transport of nucleic acid drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cationic lipid materials are used for delivering nucleic acid drugs across the blood-brain barrier, then delivery efficiency is improved, but neurotoxicity and immunogenicity increase
Solution Approach 1:
The patent modifies the chemical structure of vincamine by changing parameters such as introducing fatty acid chains at different positions and varying chain lengths. This structural parameter modification reduces the cationic charge density while maintaining BBB penetration capability, thereby reducing neurotoxicity and immunogenicity while preserving delivery efficiency
Solution Approach 2:
The patent creates composite lipid structures by combining vincamine core with various fatty acid chains (such as palmitic acid, stearic acid, oleic acid). These composite structures integrate the BBB-penetrating capability of vincamine with the delivery properties of lipid chains, achieving effective nucleic acid drug delivery with reduced toxicity
2Reliability
If lipid nanoparticles with high positive charge are used to encapsulate nucleic acid drugs, then encapsulation efficiency is improved, but hepatic distribution increases
Solution Approach 1:
The patent modifies the charge parameters of the lipid nanoparticles by using vincamine derivatives with controlled cationic charge. The modified structures maintain sufficient positive charge for nucleic acid encapsulation but reduce excessive positive charge that causes liver targeting, thereby shifting distribution away from the liver while maintaining encapsulation efficiency
3Reliability
If direct administration into the central nervous system is performed, then drug delivery efficiency is improved, but invasiveness and risk of infection increase
Solution Approach 1:
The patent uses vincamine derivatives as intermediary carriers that can traverse the blood-brain barrier naturally. These modified vincamine structures act as mediators between intravenous administration and brain target sites, enabling drug delivery without direct CNS injection while avoiding the invasiveness and infection risks associated with surgical approaches
4Reliability
If blood-brain barrier disruption techniques are used, then drug introduction into the brain is improved, but plasma protein leakage and neurotoxicity increase
Solution Approach 1:
The patent employs vincamine derivatives as intermediary carriers that can pass through the intact blood-brain barrier without requiring disruption. These modified structures facilitate drug transport across the barrier while maintaining its integrity, thereby avoiding plasma protein leakage and the neurotoxicity associated with barrier disruption techniques
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vincamine derivatives effectively deliver nucleic acid drugs to the brain while maintaining neuroprotective effects and reducing toxicity, enhancing brain-targeted drug delivery for treating brain diseases.
Implementation Method 1
the indole heterocycles in the vincamine alkaloids contain protonatable amine groups, which are expected to enable electrostatic with nucleic acid drugs, facilitating their encapsulation and delivery into cells
Implementation Method 2
Development of vincamine derivatives with modified tail chains and ionizable tertiary amine groups to enhance lipophilicity and charge-mediated delivery, facilitating penetration across the blood-brain barrier
Data Source
AI summary
The present application relates to a vincamine derivative, a preparation method therefor, and use thereof, and belongs to the technical field of preparation of vincamine derivatives. The vincamine derivative has the following advantages: (i) Modification of the tail chain increases the lipid solubility of vincamine compounds without affecting the cerebral blood flow regulation of vincamine itself, thereby helping the carried drug penetrate the blood-brain barrier, exert a brain-protective effect, and improve cerebral microcirculatory disorders. (ii) The tertiary amine group in the parent nucleus structure of the vincamine derivative is ionizable under acidic conditions, which enables efficient delivery and lysosomal escape of nucleic acid drugs through charge adsorption, thereby improving intracellular transport. (iii) The vincamine derivative inherits various pharmacological activities inherent to vincamine, and has high safety. Therefore, the vincamine derivative has good application prospects in brain-targeted delivery of drugs for treating brain diseases.